ABSTRACT
BACKGROUND: Although anti-IgE antibody (Ab) therapy was recently shown to be effective in patients with bronchial asthma, no study has reported the effect of IgE therapy in the prevention of wasp venom anaphylaxis. In this study, we used a mouse model of wasp venom allergy to investigate the effect of anti-IgE Ab on wasp venom anaphylaxis. METHODS: We developed a mouse model of wasp venom allergy by intraperitoneally (i.p.) injecting wasp venom into BALB/c mice twice on experimental day (day) 0 and 7. On day 20, a group of mice received an i.p. injection of mouse anti-IgE Ab as a pretreatment, and another group received rat anti-IgG1 Ab. On day 21, the animals were challenged by i.p. injection of wasp venom, and 30 min later, body temperature was measured and serum levels of leukotriene (LT) B4 and LTC4 were determined using enzyme immunoassay. RESULTS: The body temperature of mice treated with anti-IgE Ab and controls before and after wasp venom challenge was 37.8±0.2 vs 37.7± 0.3°C before challenge and 37.8±0.2 vs 37.1± 0.3°C after challenge, respectively, showing that anti-IgE Ab treatment significantly prevented body temperature from falling (p <0.05). Furthermore, anti-IgE Ab treatment reduced total serum IgE levels in the treated mice (42.2±15.9 pg/ml), compared with controls (105.9±23.1 pg/ml, p <0.05), and inhibited the secretion of LTC4 in the treated mice (32.0±18.8 pg/ml), but not in the controls (162.4±12.4 pg/ml, p <0.05), following challenge with wasp venom. CONCLUSION: The results of the present study indicate that anti-IgE Ab treatment is an effective preventive measure against wasp venom-induced anaphylaxis.
Subject(s)
Anaphylaxis/drug therapy , Immunoglobulin E/immunology , Wasp Venoms/toxicity , Anaphylaxis/blood , Anaphylaxis/chemically induced , Anaphylaxis/immunology , Animals , Body Temperature/drug effects , Body Temperature/immunology , Disease Models, Animal , Humans , Leukotriene B4/blood , Leukotriene B4/immunology , Leukotriene C4/blood , Leukotriene C4/immunology , Mice , RatsABSTRACT
BACKGROUND AND OBJECTIVES: The current circumstances of patients treated with home oxygen therapy (HOT) for respiratory failure are understood relatively well, whereas those of HOT patients with heart failure has not been extensively examined. Furthermore, investigation of the fundamental realities of disease checkups cooperation between specialist hospitals and clinics regarding HOT patients has not been satisfactory. For these reasons, we attempted to clarify the circumstances of HOT patients at clinics, respiratory specialist hospitals, and cardiovascular specialist hospitals, in the context of those who work in the medical sphere in Japan (approx. 2 million people). METHODS: An epidemiological survey was simultaneously sent to district clinics, respiratory specialist hospitals, and cardiovascular specialist hospitals, all located in Tochigi Prefecture in Japan, and which were anticipated to be involved in HOT. RESULTS AND CONCLUSIONS: HOT was widely performed in all respiratory specialist hospitals, but only in 55% of clinics and in 67% of cardiovascular specialist hospitals. Among the total number of patients given HOT, the rate of patients with heart failure was 15%, 80% of whom had left-sided heart failure. This value was five times higher than that reported in a nationwide investigation in Japan. Since patients with advanced heart failure were highly comorbid with sleep-disordered breathing (SDB), non-invasive ventilation with continuous positive airway pressure (CPAP) instead of HOT was frequently given to these patients as first-line therapy. Checkups cooperation appeared relatively close among respiratory specialist hospitals, but not between cardiovascular specialist hospitals and district clinics.
